It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

The ACC/AHA Task Force on Practice Guidelines was formed to make recommendations
regarding the diagnosis and treatment of patients with known or suspected cardiovascular …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Background Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an
intravenous blocker of the adenosine diphosphate receptor P2Y12. This agent might have a …

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the
Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction …

Background—The antiplatelet effects of the Platelet Inhibition and Patient Outcomes
(PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they …

Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its
morbidity and mortality. Because little advance has been made in outcomes following ST …

Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A 2
and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance …

Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …